Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Gepa-merz
2. L-ornithine-l-aspartate
3. Orn-asp
4. Ornithine Aspartate
5. Ornithylaspartate
1. 3230-94-2
2. L-ornithine-l-aspartate
3. L-ornithine L-aspartate Salt
4. Ornithine Aspartate
5. (s)-2,5-diaminopentanoic Acid Compound With (s)-2-aminosuccinic Acid (1:1)
6. Ornithine Aseparate
7. L-aspartic Acid, Compd. With L-ornithine (1:1)
8. (2s)-2-aminobutanedioic Acid;(2s)-2,5-diaminopentanoic Acid
9. Ornithine Aspartate (l-ornithine L-aspartate)
10. Mfcd00058084
11. Hepa-merz (tn)
12. Lola
13. Ruigan
14. Schembl361185
15. Dtxsid30883964
16. Bcp13530
17. Hy-a0282
18. Ornithine Aspartate [who-dd]
19. L-ornithine L-aspartate Salt, Powder
20. Akos015998595
21. L-ornithine-l-aspartate (salt)
22. Ornithine L-form Aspartate [mi]
23. As-12577
24. L-ornithine, L-aspartate (1:1)
25. Aspartic Acid Compd. With Ornithine
26. Cs-0019764
27. O0440
28. Ornithine, L-, L-aspartate (1:1)
29. D08303
30. D70545
31. A821231
32. Q-102756
33. Q27281401
34. (s)-2,5-diaminopentanoic Acid (s)-2-aminosuccinic Acid Salt
35. (s)-2,5-diaminopentanoicacidcompoundwith(s)-2-aminosuccinicacid(1:1)
| Molecular Weight | 265.26 g/mol |
|---|---|
| Molecular Formula | C9H19N3O6 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 265.12738533 g/mol |
| Monoisotopic Mass | 265.12738533 g/mol |
| Topological Polar Surface Area | 190 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 228 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
HepaCure (L-Ornithine L-Aspartate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Acute-On-Chronic Liver Failure.
Lead Product(s): L-Ornithine L-aspartate,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: HepaCure
Study Phase: Phase I/ Phase IIProduct Type: Amino Acid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 14, 2023
Lead Product(s) : L-Ornithine L-aspartate,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HepaCure (L-Ornithine L-Aspartate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Acute-On-Chronic Liver Failure.
Product Name : HepaCure
Product Type : Amino Acid
Upfront Cash : Inapplicable
August 14, 2023
Details:
The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.
Lead Product(s): L-Ornithine L-aspartate,Inapplicable
Therapeutic Area: Neurology Brand Name: Hepa-Merz
Study Phase: Approved FDFProduct Type: Amino Acid
Sponsor: Hong Kong Winhealth Pharma Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 08, 2021
Lead Product(s) : L-Ornithine L-aspartate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in Chi...
Details : The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.
Product Name : Hepa-Merz
Product Type : Amino Acid
Upfront Cash : Undisclosed
March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
Market Place
ABOUT THIS PAGE
32
PharmaCompass offers a list of L-Ornithine L-aspartate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right L-Ornithine L-aspartate manufacturer or L-Ornithine L-aspartate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred L-Ornithine L-aspartate manufacturer or L-Ornithine L-aspartate supplier.
PharmaCompass also assists you with knowing the L-Ornithine L-aspartate API Price utilized in the formulation of products. L-Ornithine L-aspartate API Price is not always fixed or binding as the L-Ornithine L-aspartate Price is obtained through a variety of data sources. The L-Ornithine L-aspartate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A L-Ornithine L-aspartate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of L-Ornithine L-aspartate, including repackagers and relabelers. The FDA regulates L-Ornithine L-aspartate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. L-Ornithine L-aspartate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of L-Ornithine L-aspartate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A L-Ornithine L-aspartate supplier is an individual or a company that provides L-Ornithine L-aspartate active pharmaceutical ingredient (API) or L-Ornithine L-aspartate finished formulations upon request. The L-Ornithine L-aspartate suppliers may include L-Ornithine L-aspartate API manufacturers, exporters, distributors and traders.
click here to find a list of L-Ornithine L-aspartate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A L-Ornithine L-aspartate DMF (Drug Master File) is a document detailing the whole manufacturing process of L-Ornithine L-aspartate active pharmaceutical ingredient (API) in detail. Different forms of L-Ornithine L-aspartate DMFs exist exist since differing nations have different regulations, such as L-Ornithine L-aspartate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A L-Ornithine L-aspartate DMF submitted to regulatory agencies in the US is known as a USDMF. L-Ornithine L-aspartate USDMF includes data on L-Ornithine L-aspartate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The L-Ornithine L-aspartate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of L-Ornithine L-aspartate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing L-Ornithine L-aspartate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for L-Ornithine L-aspartate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture L-Ornithine L-aspartate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain L-Ornithine L-aspartate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a L-Ornithine L-aspartate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of L-Ornithine L-aspartate suppliers with NDC on PharmaCompass.
L-Ornithine L-aspartate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of L-Ornithine L-aspartate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right L-Ornithine L-aspartate GMP manufacturer or L-Ornithine L-aspartate GMP API supplier for your needs.
A L-Ornithine L-aspartate CoA (Certificate of Analysis) is a formal document that attests to L-Ornithine L-aspartate's compliance with L-Ornithine L-aspartate specifications and serves as a tool for batch-level quality control.
L-Ornithine L-aspartate CoA mostly includes findings from lab analyses of a specific batch. For each L-Ornithine L-aspartate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
L-Ornithine L-aspartate may be tested according to a variety of international standards, such as European Pharmacopoeia (L-Ornithine L-aspartate EP), L-Ornithine L-aspartate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (L-Ornithine L-aspartate USP).
